<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512343</url>
  </required_header>
  <id_info>
    <org_study_id>02-12 LS</org_study_id>
    <nct_id>NCT00512343</nct_id>
  </id_info>
  <brief_title>Synovial Fluid Bank From Arthritic Patients</brief_title>
  <official_title>Establishment of a Bank of Synovial Fluids and Paired Sera From Arthritic Patients for the Evaluation of New Methods Facilitating the Diagnosis and the Monitoring of Progression and Therapy of Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilles Boire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Arthritis Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this group project is to collect synovial fluid (SF) and paired sera and&#xD;
      carry out preclinical studies to evaluate, alone or by combination testings, the potential of&#xD;
      novel biomarkers for their prevalence and diagnostic/prognostic values in patients with&#xD;
      arthritis, and to determine how therapeutic intervention regulate their levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our group has developed interdisciplinary expertise in biomarkers related to distinct aspects&#xD;
      of inflammation-induced joint damage, most notably those associated with degradation of&#xD;
      components of the extracellular matrix, bone loss, or associated with post-translational&#xD;
      changes on protease inhibitors.&#xD;
&#xD;
      The objectives of this group project is to collect SF and paired sera and carry out&#xD;
      preclinical studies to evaluate, alone or by combination testings, the potential of novel&#xD;
      biomarkers for their prevalence and diagnostic/prognostic values in patients with arthritis,&#xD;
      and to determine how therapeutic intervention regulate their levels.&#xD;
&#xD;
      More specifically, we will study (1) biomarkers associated with osteoclastic bone resorption&#xD;
      and synthesis/degradation of cartilage, (2) inhibitors of enzymes (calpastatin) that are&#xD;
      preferentially targeted by rheumatoid patients, as well as (3) enzymes (e.g. Matrix&#xD;
      Metalloproteinases (MMPs)) responsible for the cleavage of components of the articular&#xD;
      cartilage.&#xD;
&#xD;
      Finally, we propose to characterize the repertoire of specific active proteases in the SF of&#xD;
      arthritic patients concomitantly to the use biomarkers (neoepitopes of cleaved collagens)&#xD;
      previously associated with cartilage destruction and synthesis to identify new targets for&#xD;
      the development of protease inhibitors for the treatment of arthritis. Furthermore, our&#xD;
      project will also provide the opportunity to test the potential of measuring the net&#xD;
      proteolytic activity by Fluorescent-Activated Substrate Conversion as a method of monitoring&#xD;
      disease activity and treatment efficiency in a clinical setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2002</start_date>
  <completion_date type="Anticipated">September 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Availability of paired synovial fluid and serum samples for exploratory studies</measure>
    <time_frame>Use with various collaborators at different times, upon request and approbation</time_frame>
    <description>Availability of paired synovial fluid and serum samples, linked with anonymized clinical and treatment data, from patients suffering from various arthritides (rheumatoid arthritis, gout and other microcrystalline arthritides, osteoarthritis, spondylarthropathies, juvenile idiopathic arthritis, and various other diseases, including inflammatory polyarthritis of recent-onset in adults</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Arthritis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Synovial fluids from joints with effusion Sereum samples drawn on the same day&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients suffering from various arthritides (rheumatoid arthritis, gout and other&#xD;
        microcristalline arthritides, osteoarthritis, spondylarthropathies, juvenile idiopathic&#xD;
        arthritis, and various other diseases, including inflammatory polyarthritis of recent-onset&#xD;
        in adults&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Significant joint effusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemorrhagic effusion&#xD;
&#xD;
          -  Traumatic effusion&#xD;
&#xD;
          -  Less than 3 ml total of collected fluid (used for routine analysis and culture)&#xD;
&#xD;
          -  Inability or refusal to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Boire, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUS and Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles Boire, MD, MSc</last_name>
    <phone>(819) 564-5261</phone>
    <email>Gilles.Boire@USherbrooke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Boire, MD, MSc</last_name>
      <phone>(819) 564-5261</phone>
      <email>Gilles.Boire@USherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>Gilles Boire, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Kilani RT, Maksymowych WP, Aitken A, Boire G, St-Pierre Y, Li Y, Ghahary A. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 2007 Aug;34(8):1650-7. Epub 2007 Jul 1.</citation>
    <PMID>17611984</PMID>
  </results_reference>
  <results_reference>
    <citation>Simard N, Boire G, de Brum-Fernandes AJ, St-Pierre Y. A novel approach to measure the contribution of matrix metalloproteinase in the overall net proteolytic activity present in synovial fluids of patients with arthritis. Arthritis Res Ther. 2006;8(4):R125.</citation>
    <PMID>16859524</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2007</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Gilles Boire</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Synovial Fluid</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Paired serum/synovial fluid samples</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

